NICE (National Institute for Health and Clinical Excellence) stirs debate over value of medical technology in maternity
This article was originally published in Clinica
The value of ensuring access to medical technology, versus its potential detrimental effect during maternity is the subject of intense debate in the UK, following last week's launch of a consultation on the subject. By the end of this year, new policy in this area will affect some 600,000 cases annually in England and Wales.
You may also be interested in...
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.